Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075441 | 0.88 | SIGMAR1 (0.44) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL101721 | 0.86 | JAK2 (0.41) | SIGMAR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1498997 | 0.85 | SIGMAR1 (0.33) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL98626 | 0.85 | JAK2 (0.35) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL872289 | 0.85 | JAK2 (0.40) | SIGMAR1JAK2JAK1DGAT1HDAC3 | |
| SCHEMBL1498970 | 0.85 | DGAT1 (0.35) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL16980124 | 0.85 | SIGMAR1 (0.36) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL99469 | 0.85 | JAK1 (0.33) | SIGMAR1JAK2JAK1DGAT1TPH1 | |
| SCHEMBL100337 | 0.84 | JAK2 (0.36) | SIGMAR1JAK2JAK1DGAT1TYK2 | |
| SCHEMBL100034 | 0.84 | JAK2 (0.33) | SIGMAR1JAK2JAK1DGAT1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | SIGMAR1 4279/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.